190 related articles for article (PubMed ID: 7749161)
1. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
Zoli W; Flamigni A; Frassineti GL; Bajorko P; De Paola F; Milandri C; Amadori D; Gasperi-Campani A
Breast Cancer Res Treat; 1995 Apr; 34(1):63-9. PubMed ID: 7749161
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Kelland LR; Abel G
Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
[TBL] [Abstract][Full Text] [Related]
3. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.
Braakhuis BJ; Hill BT; Dietel M; Kelland LR; Aapro MS; Zoli W; Lelieveld P
Anticancer Res; 1994; 14(1A):205-8. PubMed ID: 7909419
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.
Silvestrini R; Zaffaroni N; Orlandi L; Oriana S
Stem Cells; 1993 Nov; 11(6):528-35. PubMed ID: 7906583
[TBL] [Abstract][Full Text] [Related]
5. Selective drug resistant human osteosarcoma cell lines.
Burns BS; Edin ML; Lester GE; Tuttle HG; Wall ME; Wani MC; Bos GD
Clin Orthop Relat Res; 2001 Feb; (383):259-67. PubMed ID: 11210963
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
Boven E; Venema-Gaberscek E; Erkelens CA; Bissery MC; Pinedo HM
Ann Oncol; 1993 Apr; 4(4):321-4. PubMed ID: 8100146
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
8. In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
Grosse PY; Bressolle F; Pinguet F
Eur J Cancer; 1998 Jan; 34(1):168-74. PubMed ID: 9624253
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Verweij J; Clavel M; Chevalier B
Ann Oncol; 1994 Jul; 5(6):495-505. PubMed ID: 7918121
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo.
Tanaka M; Obata T; Sasaki T
Eur J Cancer; 1996 Feb; 32A(2):226-30. PubMed ID: 8664032
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
Anand A; Anand A
J Natl Cancer Inst; 1995 Nov; 87(21):1642. PubMed ID: 7563210
[No Abstract] [Full Text] [Related]
13. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
14. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
15. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Fumoleau P; Perrocheau G; Maugard-Louboutin C; Lemevel B
Bull Cancer; 1995 Aug; 82(8):629-36. PubMed ID: 7492819
[TBL] [Abstract][Full Text] [Related]
16. [The effect of docetaxel on malignant tumors].
Eckhardt S
Orv Hetil; 1998 Apr; 139(15):867-72. PubMed ID: 9579099
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
18. Taxol and taxotere in bladder cancer: in vitro activity and urine stability.
Rangel C; Niell H; Miller A; Cox C
Cancer Chemother Pharmacol; 1994; 33(6):460-4. PubMed ID: 7907952
[TBL] [Abstract][Full Text] [Related]
19. Evolution in the treatment of advanced breast cancer.
Crown J
Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
[TBL] [Abstract][Full Text] [Related]
20. Taxoids in combination chemotherapy for metastatic breast cancer.
Dieras V; Fumoleau P; Bourgeois H; Misset JL; Azli N; Pouillart P
Anticancer Drugs; 1996 Aug; 7 Suppl 2():47-52. PubMed ID: 8862712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
